← All organizations
Highest phase reached
Phase 3
Timeline
1990s
- Jun 1, 1991
Accord Research— Founded
2020s
- Apr 17, 2020
cinacalcet— Marketing Organization
- Aug 24, 2020
naltrexone— NDA Secondary Org
Drugs by trial phase (31 distinct, 21 trials)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (17 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Anus Neoplasms
- Biliary Tract Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Merkel Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Fallopian Tube Neoplasms
- Hypersensitivity
- Lung Neoplasms
- Melanoma
- Mesothelioma
- Microsatellite Instability
- Ovarian Neoplasms
- Prostatic Neoplasms
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Thymus Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
Marketed drugs (149)
Recent trials (35)
- NCT05615818CollaboratorPhase 3Jul 18, 2024
- NCT06163391Lead sponsorPhase 1Apr 30, 2024
- NCT05619172Lead sponsorPhase 2Dec 31, 2022
- NCT05256381Lead sponsorPhase 2Jun 21, 2022
- NCT05525286Lead sponsorPhase 1/Phase 2Mar 31, 2022
- NCT05120271CollaboratorPhase 1/Phase 2Jan 31, 2022
- NCT05120271Study directorPhase 1/Phase 2Jan 31, 2022
- NCT05120271Lead sponsorPhase 1/Phase 2Jan 31, 2022
- NCT03905902Lead sponsorPhase 3Sep 30, 2019
- NCT03905902Study directorPhase 3Sep 30, 2019
- NCT04234113Lead sponsorPhase 1Jun 13, 2019
- NCT03514836Study directorPhase 1/Phase 2May 23, 2018
- NCT03514836Lead sponsorPhase 1/Phase 2May 23, 2018
- NCT03657966Study directorPhase 2Nov 23, 2017
- NCT03657966Lead sponsorPhase 2Nov 23, 2017
Details
- Founded
- Prague, CZ Jun 1, 1991
- Last known activity
- May 15, 2026
Notes
CRO